Though we’ve recently observed some improvement in U.S. biosimilar penetration, market entry and uptake still consistently ...

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual ...

“Biosimilars can benefit people in a more sustainable way for healthcare systems,” said Eran Gefen, Head of Global Medical ...

The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability.

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

Health Affairs' Editor-in-Chief Alan Weil interviews Janice Jhang of Harvard University about her recent paper that explores how regulatory and market forces are driving adoption of biosimilars.

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...

The agreement covers biosimilars for oncology and fertility medications.

Cigna projected 2025 profit growth of at least 10% on Thursday, after posting quarterly results that beat Wall Street ...